## *Supporting Information*

## **Aptamer Recognition of Multiplexed Small-Molecule-Functionalized Substrates**

Nako Nakatsuka,<sup>1,2</sup> Huan H. Cao,<sup>1,2</sup> Stephanie Deshayes,<sup>3</sup> Arin L. Melkonian,<sup>3</sup> Andrea M. Kasko,<sup>2,3</sup> Paul S. Weiss,<sup>1,2,4</sup> and Anne M. Andrews<sup>1,2,5\*</sup>

<sup>1</sup>Department of Chemistry and Biochemistry, <sup>2</sup>California NanoSystems Institute,  $3$ Department of Bioengineering,  $4$ Department of Materials Science and Engineering,  $5$ Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience & Human Behavior, and Hatos Center for Neuropharmacology, University of California, Los Angeles, Los Angeles, CA 90095, United States

\*To whom correspondence should be addressed: aandrews@mednet.ucla.edu



Figure S1. Optimizing surface-tethered small molecule densities. (Left) Different ratios of hydroxyl-terminated alkanethiols (background molecules; hydroxyl triethylene glycol (undecanethiol) (TEG)) *vs.* carboxyl-terminated alkanethiols (small-molecule tethers; carboxyl hexa(ethylene glycol) undecanethiol (HEG)) were incubated in each channel. Representative fluorescence image for dopamine aptamer recognition of dopamine functionalized channels. **(Right)** Maximal relative fluorescence intensities were observed for 80% TEG:20% HEG. This ratio was used for all subsequent experiments. Error bars are standard errors of the means for  $N=3$  substrates. Group means were significantly different *\*P*<0.05 and  $\dagger$ *†P*<0.01 *vs.* the 80:20 TEG:HEG ratio.







**4 – 20 µM DA aptamer + 10 µM DA**   $5 - 20 \mu M DA$  aptamer + 20  $\mu M DA$  $6 - 20 \mu M DA$  aptamer + 50  $\mu M DA$ 

**Figure S2.** Representative fluorescence images for the competitive displacement experiment to investigate reversible binding of the dopamine (DA) aptamer to surface-tethered dopamine. A different concentration of free dopamine  $(0-50 \mu M)$  was added to each channel in different orders on different substrates. Binding was quantified for  $N=4$  substrates in Figure 3A.



**Figure S3.** *L*-Tryptophan aptamer capture on patterned substrates. (A) Schematic (not to scale) of patterning and functionalization of *L*-tryptophan. **(B)** Substrates were incubated with the 34-base *L*-tryptophan-specific aptamer sequence or (C) a scrambled sequence with the same numbers of each nucleotide as the correct sequence but randomized to generate a different secondary structure. The secondary structure of the correct and scrambled sequences were generated using *Mfold.* Substrates were imaged at an emission wavelength of 525 nm for AlexaFluor® 488 (excitation at 490 nm).



**Figure S4.** Selectivity of dopamine and *L*-tryptophan aptamers. **(A)** Patterned *L-*tryptophan-functionalized substrates imaged at an emission wavelength of 605 nm for AlexaFluor® 546 (excitation at 556 nm) to visualize bound dopamine aptamers. **(B)** Patterned dopamine-functionalized substrates imaged at an emission wavelength of 525 nm for AlexaFluor<sup>®</sup> 488 (excitation at 490 nm) to visualize bound L-tryptophan aptamers. In both cases, no observable patterns were detected indicating minimal cross-reactivity for the incorrect targets.